<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYALURONIDASE, OVINE</span><br/>(hi-a-lu-ron'i-dase)<br/><span class="topboxtradename">Amphadase, </span><span class="topboxtradename">Vitrase<br/></span><b>Classifications:</b> <span class="classification">enzyme</span>; <span class="classification">absorption and dispersing enhancer</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 units/mL and 200 units/mL for injection; lyophilized powder, 6200 units</p>
<h1><a name="action">Actions</a></h1>
<p>Hyaluronidase is a diffusing substance that modifies the permeability of connective tissue through the hydrolysis of hyaluronic
         acid found in the intercellular substance of connective tissue. It temporarily decreases the viscosity of cellular cement
         and promotes diffusion of injected fluids or exudates, adding to their absorption.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It increases the absorption and dispersion of solutions in the intercellular spaces.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjuvant to increase the absorption and dispersion of other injected drugs; hypodermoclysis; adjunct in subcutaneous urography
         for improving resorption of radiopaque agents.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Adjunct for ophthalmic anesthesia, treatment of vitreous hemorrhage and diabetic retinopathy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to hyaluronidase or any other ingredient in formulation; concurrent use with dopamine or alpha-agonist drugs;
         injection into infected or acutely inflamed area, area of swelling due to bites or stings; corneal injection; injection by
         IV.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C); lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjuvant to Increase the Absorption and Dispersion of Other Drugs</span><br/><span class="rdage">Adult:</span> <span class="rdroute"></span> 150 units (range: 50300) added to solution<br/><span class="rdage">Child:</span> <span class="rdroute"></span> 150 units (range: 50300) added to solution<br/><br/><span class="indicationtitle">Hypodermoclysis</span><br/><span class="rdage">Adult:</span> <span class="rdroute"></span> 15 units added to each 100 mL of fluid<br/><br/><span class="indicationtitle"></span><br/><span class="rdage">Child <img src="../images/special/greaterorequal.gif"/> 3 y:</span> <span class="rdroute"></span> 15 units added to each 100 mL of fluid<br/><br/><span class="indicationtitle">Subcutaneous Urography</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 75 units prior to contrast medium<br/><span class="rdage">Child:</span> <span class="rdroute">SC</span> 75 units prior to contrast medium<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous or Solution Additive</span><br/><ul>
<li>	Reconstitute vial with 6.2 mL NS for injection to yield 1000 U/mL. Apply the 5-micron filter needle to the 1 mL syringe in
            injection kit and further dilute: To produce 50 U/mL, withdraw 0.05 mL reconstituted solution and add 0.95 mL NS. To produce
            75 U/mL, withdraw 0.075 mL reconstituted solution and add 0.925 mL NS. To produce 150 U/mL, withdraw 0.15 mL reconstituted
            solution and add 0.85 mL NS. To produce 300 U/mL, withdraw 0.3 mL reconstituted solution and add 0.7 mL NS. Use immediately
            after preparation.
         </li>
<li>	Give SC prior to contrast media. Do not inject near an infected or acutely inflamed area.</li>
<li>	Store unopened vial at 2°8° C (35°46° F). After reconstitution, store at 20°25°
            C (59°77° F), and use within 6 h. Protect from light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Edema. <span class="typehead">Other:</span> Injection site reaction (e.g., erythema, irritation); enhanced adverse events associated with coadministered drugs.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">salicylates</span>, <span class="classification">corticosteroids</span>, <span class="classification">estrogens</span>, or <span class="classification">h<sub>1</sub>-blockers</span> may confer partial resistant to the action of hyaluronidase in some tissues. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>	Monitor for S&amp;S of hypersensitivity: urticaria, erythema, chills, nausea, vomiting, dizziness, tachycardia, and hypotension.
            Withhold and notify physician if hypersensitivity occurs.
         </li>
<li>	Note: Those receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines may require larger amounts
            of hyaluronidase for equivalent dispersing effect.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Report immediately any of the following: rash, itching, chills, nausea, vomiting, dizziness, or palpitations.</li>
<li>	Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>